{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:01:16Z","timestamp":1791900076251,"version":"4.3.4"},"reference-count":160,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s12035-025-04818-4","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T05:06:28Z","timestamp":1742274388000},"page":"9365-9384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["New Insights on the Potential Role of Pyroptosis in Parkinson\u2019s Neuropathology and Therapeutic Targeting of NLRP3 Inflammasome with Recent Advances in Nanoparticle-Based miRNA Therapeutics"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9555-7300","authenticated-orcid":false,"given":"Hebatallah M.","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4191-9825","authenticated-orcid":false,"given":"Esraa","family":"Atef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer E.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"issue":"47A","key":"4818_CR1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.9734\/jpri\/2021\/v33i47A33082","volume":"33","author":"P Supriya","year":"2021","unstructured":"Supriya P, Rajaram S (2021) Literature review on history and pharmacotherapy of Parkinsons disease. J Pharm Res Int 33(47A):839\u2013849","journal-title":"J Pharm Res Int"},{"key":"4818_CR2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.expneurol.2003.08.008","volume":"184","author":"D Brooks","year":"2003","unstructured":"Brooks D et al (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson\u2019s disease. Exp Neurol 184:68\u201379","journal-title":"Exp Neurol"},{"issue":"1","key":"4818_CR3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41531-022-00280-4","volume":"8","author":"B Brakedal","year":"2022","unstructured":"Brakedal B et al (2022) A nationwide study of the incidence, prevalence and mortality of Parkinson\u2019s disease in the Norwegian population. NPJ Park Dis 8(1):19","journal-title":"NPJ Park Dis"},{"issue":"3","key":"4818_CR4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s10038-022-01058-5","volume":"68","author":"M Funayama","year":"2023","unstructured":"Funayama M et al (2023) Molecular genetics of Parkinson\u2019s disease: contributions and global trends. J Hum Genet 68(3):125\u2013130","journal-title":"J Hum Genet"},{"issue":"12","key":"4818_CR5","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.3390\/antiox11122467","volume":"11","author":"S Pyatha","year":"2022","unstructured":"Pyatha S et al (2022) Association between heavy metal exposure and Parkinson\u2019s disease: a review of the mechanisms related to oxidative stress. Antioxidants 11(12):2467","journal-title":"Antioxidants"},{"key":"4818_CR6","doi-asserted-by":"crossref","first-page":"837579","DOI":"10.3389\/ftox.2022.837579","volume":"4","author":"M Nabi","year":"2022","unstructured":"Nabi M, Tabassum N (2022) Role of environmental toxicants on neurodegenerative disorders. Front Toxicol 4:837579","journal-title":"Front Toxicol"},{"issue":"10291","key":"4818_CR7","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","volume":"397","author":"BR Bloem","year":"2021","unstructured":"Bloem BR, Okun MS, Klein C (2021) Parkinson\u2019s disease. Lancet 397(10291):2284\u20132303","journal-title":"Lancet"},{"key":"4818_CR8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s00018-014-1774-1","volume":"72","author":"JN Le Grand","year":"2015","unstructured":"Le Grand JN et al (2015) Neural stem cells in Parkinson\u2019s disease: a role for neurogenesis defects in onset and progression. Cell Mol Life Sci 72:773\u2013797","journal-title":"Cell Mol Life Sci"},{"issue":"3","key":"4818_CR9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00011-022-01676-x","volume":"72","author":"Q-K Lv","year":"2023","unstructured":"Lv Q-K et al (2023) Role of \u03b1-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson\u2019s disease. Inflamm Res 72(3):443\u2013462","journal-title":"Inflamm Res"},{"issue":"2","key":"4818_CR10","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009399","volume":"2","author":"L Stefanis","year":"2012","unstructured":"Stefanis L (2012) \u03b1-Synuclein in Parkinson\u2019s disease. Cold Spring Harb Perspect Med 2(2):a009399","journal-title":"Cold Spring Harb Perspect Med"},{"key":"4818_CR11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175300","volume":"934","author":"M Khot","year":"2022","unstructured":"Khot M et al (2022) NLRP3 inflammasomes: a potential target to improve mitochondrial biogenesis in Parkinson\u2019s disease. Eur J Pharmacol 934:175300","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"4818_CR12","doi-asserted-by":"crossref","first-page":"4676","DOI":"10.3390\/ijms22094676","volume":"22","author":"K Badanjak","year":"2021","unstructured":"Badanjak K et al (2021) The contribution of microglia to neuroinflammation in Parkinson\u2019s disease. Int J Mol Sci 22(9):4676","journal-title":"Int J Mol Sci"},{"key":"4818_CR13","doi-asserted-by":"crossref","unstructured":"Gordon R et al (2018) Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med\u00a010(465):eaah4066.","DOI":"10.1126\/scitranslmed.aah4066"},{"key":"4818_CR14","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2021.101263","volume":"67","author":"PA Dion\u00edsio","year":"2021","unstructured":"Dion\u00edsio PA, Amaral JD, Rodrigues CMP (2021) Oxidative stress and regulated cell death in Parkinson\u2019s disease. Ageing Res Rev 67:101263","journal-title":"Ageing Res Rev"},{"issue":"1","key":"4818_CR15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s11658-023-00516-y","volume":"29","author":"J Liang","year":"2024","unstructured":"Liang J et al (2024) The pyroptosis mediated biomarker pattern: an emerging diagnostic approach for Parkinson\u2019s disease. Cell Mol Biol Lett 29(1):7","journal-title":"Cell Mol Biol Lett"},{"key":"4818_CR16","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155019","volume":"120","author":"P Huan","year":"2023","unstructured":"Huan P et al (2023) Qiji Shujiang granules alleviates dopaminergic neuronal injury of Parkinson\u2019s disease by inhibiting NLRP3\/caspase-1 pathway mediated pyroptosis. Phytomedicine 120:155019","journal-title":"Phytomedicine"},{"key":"4818_CR17","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.bbi.2024.02.001","volume":"117","author":"A Oladapo","year":"2024","unstructured":"Oladapo A et al (2024) Role of pyroptosis in the pathogenesis of various neurological diseases. Brain Behav Immun 117:428\u2013446","journal-title":"Brain Behav Immun"},{"issue":"s1","key":"4818_CR18","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.3233\/JPD-223338","volume":"12","author":"S Jewell","year":"2022","unstructured":"Jewell S, Herath AM, Gordon R (2022) Inflammasome activation in Parkinson\u2019s disease. J Parkinsons Dis 12(s1):S113\u2013s128","journal-title":"J Parkinsons Dis"},{"issue":"1","key":"4818_CR19","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12929-021-00775-x","volume":"28","author":"M-C Kuo","year":"2021","unstructured":"Kuo M-C et al (2021) The role of noncoding RNAs in Parkinson\u2019s disease: biomarkers and associations with pathogenic pathways. J Biomed Sci 28(1):78","journal-title":"J Biomed Sci"},{"key":"4818_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6524-3_1","volume":"1509","author":"A Vishnoi","year":"2017","unstructured":"Vishnoi A, Rani S (2017) MiRNA biogenesis and regulation of diseases: an overview. MicroRNA profiling: Methods and protocols. 1509:1\u201310. https:\/\/doi.org\/10.1007\/978-1-4939-6524-3_1","journal-title":"MicroRNA profiling: Methods and protocols."},{"key":"4818_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6524-3_1","volume":"1509","author":"A Vishnoi","year":"2017","unstructured":"Vishnoi A, Rani S (2017) MiRNA biogenesis and regulation of diseases: an overview. Meth Mol Biol 1509:1\u201310. https:\/\/doi.org\/10.1007\/978-1-4939-6524-3_1","journal-title":"Meth Mol Biol"},{"issue":"2","key":"4818_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/s0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116(2):281\u201397. https:\/\/doi.org\/10.1016\/s0092-8674(04)00045-5","journal-title":"Cell."},{"key":"4818_CR23","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.101915","volume":"87","author":"S Rajan","year":"2023","unstructured":"Rajan S et al (2023) Understanding the involvement of innate immunity and the Nrf2-NLRP3 axis on mitochondrial health in Parkinson\u2019s disease. Ageing Res Rev 87:101915","journal-title":"Ageing Res Rev"},{"issue":"22","key":"4818_CR24","doi-asserted-by":"crossref","first-page":"5649","DOI":"10.3390\/ijms20225649","volume":"20","author":"SY Goh","year":"2019","unstructured":"Goh SY et al (2019) Role of microRNAs in Parkinson\u2019s disease. Int J Mol Sci 20(22):5649","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4818_CR25","first-page":"1","volume":"12","author":"KM Taufiqul Arif","year":"2020","unstructured":"Taufiqul Arif KM et al (2020) Regulatory mechanisms of epigenetic mirna relationships in human cancer and potential as therapeutic targets. Cancers 12(10):1\u201326","journal-title":"Cancers"},{"key":"4818_CR26","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111826","volume":"213","author":"SN Uppala","year":"2023","unstructured":"Uppala SN et al (2023) Involvement of miRNA on epigenetics landscape of Parkinson\u2019s disease: from pathogenesis to therapeutics. Mech Ageing Dev 213:111826","journal-title":"Mech Ageing Dev"},{"issue":"7","key":"4818_CR27","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s00018-022-04389-w","volume":"79","author":"M Rajendran","year":"2022","unstructured":"Rajendran M et al (2022) Restricting \u03b1-synuclein transport into mitochondria by inhibition of \u03b1-synuclein\u2013VDAC complexation as a potential therapeutic target for Parkinson\u2019s disease treatment. Cell Mol Life Sci 79(7):368","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"4818_CR28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1007\/s12035-021-02596-3","volume":"59","author":"IN Serratos","year":"2022","unstructured":"Serratos IN et al (2022) An update on the critical role of \u03b1-synuclein in Parkinson\u2019s disease and other synucleinopathies: from tissue to cellular and molecular levels. Mol Neurobiol 59(1):620\u2013642","journal-title":"Mol Neurobiol"},{"issue":"1","key":"4818_CR29","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bph.15684","volume":"179","author":"ME Haque","year":"2022","unstructured":"Haque ME et al (2022) Targeting \u03b1-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson\u2019s disease. Br J Pharmacol 179(1):23\u201345","journal-title":"Br J Pharmacol"},{"issue":"4","key":"4818_CR30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.3390\/pharmaceutics10040269","volume":"10","author":"DM Teleanu","year":"2018","unstructured":"Teleanu DM et al (2018) Blood-brain delivery methods using nanotechnology. Pharmaceutics 10(4):269","journal-title":"Pharmaceutics"},{"key":"4818_CR31","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jconrel.2016.06.005","volume":"235","author":"C Saraiva","year":"2016","unstructured":"Saraiva C et al (2016) MicroRNA-124 loaded nanoparticles enhance brain repair in Parkinson\u2019s disease. J Control Release 235:291\u2013305","journal-title":"J Control Release"},{"issue":"8","key":"4818_CR32","first-page":"1356","volume":"14","author":"KP Tryphena","year":"2023","unstructured":"Tryphena KP et al (2023) Mitochondrial complex I as a pathologic and therapeutic target for Parkinson\u2019s disease. ACS Chem Neurosci 14(8):1356\u20131368","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"4818_CR33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.neulet.2010.09.061","volume":"486","author":"SJ Chinta","year":"2010","unstructured":"Chinta SJ et al (2010) Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 486(3):235\u2013239","journal-title":"Neurosci Lett"},{"key":"4818_CR34","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40035-023-00354-0","volume":"12","author":"P Naren","year":"2023","unstructured":"Naren P, Samim K, Tryphena K (2023) Microtubule acetylation dyshomeostasis in Parkinson\u2019s disease. Transl Neurodegener 12:20","journal-title":"Transl Neurodegener"},{"key":"4818_CR35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3389\/fnins.2020.00719","volume":"14","author":"DJ Dues","year":"2020","unstructured":"Dues DJ, Moore DJ (2020) LRRK2 and protein aggregation in Parkinson\u2019s disease: insights from animal models. Front Neurosci 14:719","journal-title":"Front Neurosci"},{"issue":"12","key":"4818_CR36","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.3390\/cells9122565","volume":"9","author":"GR Jeong","year":"2020","unstructured":"Jeong GR, Lee BD (2020) Pathological functions of LRRK2 in Parkinson\u2019s disease. Cells 9(12):2565","journal-title":"Cells"},{"issue":"1","key":"4818_CR37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nri.2015.7","volume":"16","author":"SM Man","year":"2016","unstructured":"Man SM, Kanneganti T-D (2016) Converging roles of caspases in inflammasome activation, cell death and innate immunity. Nat Rev Immunol 16(1):7\u201321","journal-title":"Nat Rev Immunol"},{"key":"4818_CR38","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.redox.2015.01.008","volume":"4","author":"A Abderrazak","year":"2015","unstructured":"Abderrazak A et al (2015) NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol 4:296\u2013307","journal-title":"Redox Biol"},{"issue":"7","key":"4818_CR39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","volume":"16","author":"P Broz","year":"2016","unstructured":"Broz P, Dixit VM (2016) Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 16(7):407\u2013420","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4818_CR40","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu P et al (2021) Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther 6(1):128","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"4818_CR41","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41420-022-01101-6","volume":"8","author":"L Lu","year":"2022","unstructured":"Lu L et al (2022) Emerging mechanisms of pyroptosis and its therapeutic strategy in cancer. Cell Death Discov 8(1):338","journal-title":"Cell Death Discov"},{"key":"4818_CR42","doi-asserted-by":"crossref","unstructured":"Liu Z et al (2020)\u00a0Caspase-1 engages full-length Gasdermin D through two distinct interfaces that mediate caspase recruitment and substrate cleavage. Immunity\u00a053(1):106\u2013114. e5","DOI":"10.1016\/j.immuni.2020.06.007"},{"issue":"3","key":"4818_CR43","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41577-019-0228-2","volume":"20","author":"P Broz","year":"2020","unstructured":"Broz P, Pelegr\u00edn P, Shao F (2020) The gasdermins, a protein family executing cell death and inflammation. Nat Rev Immunol 20(3):143\u2013157","journal-title":"Nat Rev Immunol"},{"key":"4818_CR44","volume":"12","author":"X Zheng","year":"2021","unstructured":"Zheng X et al (2021) The role and mechanism of pyroptosis and potential therapeutic targets in sepsis: a review. Front Immunol 12:711939","journal-title":"Front Immunol"},{"issue":"9","key":"4818_CR45","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.apsb.2021.02.006","volume":"11","author":"BE Burdette","year":"2021","unstructured":"Burdette BE et al (2021) Gasdermin D in pyroptosis. Acta Pharm Sin B 11(9):2768\u20132782","journal-title":"Acta Pharm Sin B"},{"issue":"11","key":"4818_CR46","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.3390\/ijms23116208","volume":"23","author":"H Zhao","year":"2022","unstructured":"Zhao H et al (2022) The role of autophagy and pyroptosis in liver disorders. Int J Mol Sci 23(11):6208","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4818_CR47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/sj.cdd.4402038","volume":"14","author":"F Martinon","year":"2007","unstructured":"Martinon F, Tschopp J (2007) Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ 14(1):10\u201322","journal-title":"Cell Death Differ"},{"issue":"28","key":"4818_CR48","doi-asserted-by":"crossref","first-page":"7858","DOI":"10.1073\/pnas.1607769113","volume":"113","author":"RA Aglietti","year":"2016","unstructured":"Aglietti RA et al (2016) GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. Proc Natl Acad Sci 113(28):7858\u20137863","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"4818_CR49","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.tibs.2016.10.004","volume":"42","author":"J Shi","year":"2017","unstructured":"Shi J, Gao W, Shao F (2017) Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci 42(4):245\u2013254","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"4818_CR50","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.immuni.2015.10.009","volume":"43","author":"D Yang","year":"2015","unstructured":"Yang D et al (2015) Caspase-11 requires the pannexin-1 channel and the purinergic P2X7 pore to mediate pyroptosis and endotoxic shock. Immunity 43(5):923\u2013932","journal-title":"Immunity"},{"issue":"4","key":"4818_CR51","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.4049\/jimmunol.1401624","volume":"194","author":"M Karmakar","year":"2015","unstructured":"Karmakar M et al (2015) Neutrophil IL-1\u03b2 processing induced by pneumolysin is mediated by the NLRP3\/ASC inflammasome and caspase-1 activation and is dependent on K+ efflux. J Immunol 194(4):1763\u20131775","journal-title":"J Immunol"},{"issue":"1","key":"4818_CR52","doi-asserted-by":"crossref","first-page":"10555","DOI":"10.1038\/ncomms10555","volume":"7","author":"M Karmakar","year":"2016","unstructured":"Karmakar M et al (2016) Neutrophil P2X7 receptors mediate NLRP3 inflammasome-dependent IL-1\u03b2 secretion in response to ATP. Nat Commun 7(1):10555","journal-title":"Nat Commun"},{"issue":"1","key":"4818_CR53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev.physiol.70.113006.100630","volume":"71","author":"A Surprenant","year":"2009","unstructured":"Surprenant A, North RA (2009) Signaling at purinergic P2X receptors. Annu Rev Physiol 71(1):333\u2013359","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"4818_CR54","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12974-022-02547-2","volume":"19","author":"M Chen","year":"2022","unstructured":"Chen M, Rong R, Xia X (2022) Spotlight on pyroptosis: role in pathogenesis and therapeutic potential of ocular diseases. J Neuroinflammation 19(1):183","journal-title":"J Neuroinflammation"},{"issue":"7661","key":"4818_CR55","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nature22393","volume":"547","author":"Y Wang","year":"2017","unstructured":"Wang Y et al (2017) Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin. Nature 547(7661):99\u2013103","journal-title":"Nature"},{"key":"4818_CR56","doi-asserted-by":"crossref","unstructured":"Neel DV et al (2023) Gasdermin-E mediates mitochondrial damage in axons and neurodegeneration. Neuron 111(8):1222\u20131240. e9","DOI":"10.1016\/j.neuron.2023.02.019"},{"key":"4818_CR57","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2022.101152","volume":"88","author":"S N\u00fcssing","year":"2022","unstructured":"N\u00fcssing S et al (2022) Beyond target cell death\u2013granzyme serine proteases in health and disease. Mol Aspects Med 88:101152","journal-title":"Mol Aspects Med"},{"issue":"24","key":"4818_CR58","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1242\/jcs.03239","volume":"119","author":"M Bots","year":"2006","unstructured":"Bots M, Medema JP (2006) Granzymes at a glance. J Cell Sci 119(24):5011\u20135014","journal-title":"J Cell Sci"},{"issue":"9","key":"4818_CR59","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/cdd.2013.59","volume":"20","author":"O Susanto","year":"2013","unstructured":"Susanto O et al (2013) Mouse granzyme A induces a novel death with writhing morphology that is mechanistically distinct from granzyme B-induced apoptosis. Cell Death Differ 20(9):1183\u20131193","journal-title":"Cell Death Differ"},{"issue":"7799","key":"4818_CR60","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41586-020-2071-9","volume":"579","author":"Z Zhang","year":"2020","unstructured":"Zhang Z et al (2020) Gasdermin E suppresses tumour growth by activating anti-tumour immunity. Nature 579(7799):415\u2013420","journal-title":"Nature"},{"key":"4818_CR61","doi-asserted-by":"crossref","unstructured":"Zhou Z et al (2020) Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells. Science 368(6494):eaaz7548","DOI":"10.1126\/science.aaz7548"},{"issue":"3","key":"4818_CR62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi L et al (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25(3):486\u2013541","journal-title":"Cell Death Differ"},{"issue":"1","key":"4818_CR63","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/imr.12287","volume":"265","author":"I Jorgensen","year":"2015","unstructured":"Jorgensen I, Miao EA (2015) Pyroptotic cell death defends against intracellular pathogens. Immunol Rev 265(1):130\u2013142","journal-title":"Immunol Rev"},{"issue":"1","key":"4818_CR64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/cr.2017.133","volume":"28","author":"Y Zhang","year":"2018","unstructured":"Zhang Y et al (2018) Plasma membrane changes during programmed cell deaths. Cell Res 28(1):9\u201321","journal-title":"Cell Res"},{"issue":"1","key":"4818_CR65","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s13046-024-03115-7","volume":"43","author":"M Hu","year":"2024","unstructured":"Hu M et al (2024) The crosstalk between immune cells and tumor pyroptosis: advancing cancer immunotherapy strategies. J Exp Clin Cancer Res 43(1):190","journal-title":"J Exp Clin Cancer Res"},{"issue":"38","key":"4818_CR66","doi-asserted-by":"crossref","first-page":"2407115","DOI":"10.1002\/adma.202407115","volume":"36","author":"Z Pan","year":"2024","unstructured":"Pan Z et al (2024) Pyroptotic-spatiotemporally selective delivery of siRNA against pyroptosis and autoimmune diseases. Adv Mater 36(38):2407115","journal-title":"Adv Mater"},{"issue":"1","key":"4818_CR67","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nprot.2006.342","volume":"2","author":"V Jackson-Lewis","year":"2007","unstructured":"Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson\u2019s disease. Nat Protoc 2(1):141\u2013151","journal-title":"Nat Protoc"},{"issue":"1","key":"4818_CR68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055375","volume":"8","author":"G Codolo","year":"2013","unstructured":"Codolo G et al (2013) Triggering of inflammasome by aggregated \u03b1\u2013synuclein, an inflammatory response in synucleinopathies. PLoS ONE 8(1):e55375","journal-title":"PLoS ONE"},{"key":"4818_CR69","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.intimp.2018.12.019","volume":"67","author":"S Wang","year":"2019","unstructured":"Wang S et al (2019) The mechanisms of NLRP3 inflammasome\/pyroptosis activation and their role in Parkinson\u2019s disease. Int Immunopharmacol 67:458\u2013464","journal-title":"Int Immunopharmacol"},{"key":"4818_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-2-14","volume":"2","author":"E Croisier","year":"2005","unstructured":"Croisier E et al (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflammation 2:1\u20138","journal-title":"J Neuroinflammation"},{"issue":"2","key":"4818_CR71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.4049\/jimmunol.0901363","volume":"183","author":"FG Bauernfeind","year":"2009","unstructured":"Bauernfeind FG et al (2009) Cutting edge: NF-\u03baB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol 183(2):787\u2013791","journal-title":"J Immunol"},{"key":"4818_CR72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.abb.2019.05.023","volume":"670","author":"E de Alba","year":"2019","unstructured":"de Alba E (2019) Structure, interactions and self-assembly of ASC-dependent inflammasomes. Arch Biochem Biophys 670:15\u201331","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"4818_CR73","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrn2038","volume":"8","author":"ML Block","year":"2007","unstructured":"Block ML, Zecca L, Hong J-S (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8(1):57\u201369","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"4818_CR74","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.nbd.2006.06.013","volume":"24","author":"CC Ferrari","year":"2006","unstructured":"Ferrari CC et al (2006) Progressive neurodegeneration and motor disabilities induced by chronic expression of IL-1\u03b2 in the substantia nigra. Neurobiol Dis 24(1):183\u2013193","journal-title":"Neurobiol Dis"},{"key":"4818_CR75","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s00702-010-0431-6","volume":"117","author":"KA Maguire-Zeiss","year":"2010","unstructured":"Maguire-Zeiss KA, Federoff HJ (2010) Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson\u2019s disease. J Neural Transm 117:1019\u20131025","journal-title":"J Neural Transm"},{"key":"4818_CR76","doi-asserted-by":"crossref","unstructured":"Kam T-I et al (2018) Poly (ADP-ribose) drives pathologic \u03b1-synuclein neurodegeneration in Parkinson\u2019s disease. Science 362(6414):eaat8407","DOI":"10.1126\/science.aat8407"},{"issue":"1","key":"4818_CR77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cell.2014.11.047","volume":"160","author":"Y Yan","year":"2015","unstructured":"Yan Y et al (2015) Dopamine controls systemic inflammation through inhibition of NLRP3 inflammasome. Cell 160(1):62\u201373","journal-title":"Cell"},{"key":"4818_CR78","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1007\/s12035-016-9980-5","volume":"54","author":"C Qiao","year":"2017","unstructured":"Qiao C et al (2017) Caspase-1 deficiency alleviates dopaminergic neuronal death via inhibiting caspase-7\/AIF pathway in MPTP\/p mouse model of Parkinson\u2019s disease. Mol Neurobiol 54:4292\u20134302","journal-title":"Mol Neurobiol"},{"key":"4818_CR79","doi-asserted-by":"crossref","unstructured":"Gordon R et al (2018) Inflammasome inhibition prevents \u03b1-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Transl Med 10(465):eaah4066","DOI":"10.1126\/scitranslmed.aah4066"},{"key":"4818_CR80","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bbi.2024.03.038","volume":"119","author":"X Zhang","year":"2024","unstructured":"Zhang X et al (2024) Pyroptosis-mediator GSDMD promotes Parkinson\u2019s disease pathology via microglial activation and dopaminergic neuronal death. Brain Behav Immun 119:129\u2013145","journal-title":"Brain Behav Immun"},{"issue":"3","key":"4818_CR81","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/mds.26488","volume":"31","author":"P Zhang","year":"2016","unstructured":"Zhang P et al (2016) C dk5-dependent activation of neuronal inflammasomes in Parkinson\u2019s disease. Mov Disord 31(3):366\u2013376","journal-title":"Mov Disord"},{"key":"4818_CR82","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jocn.2019.04.004","volume":"65","author":"R Zeng","year":"2019","unstructured":"Zeng R et al (2019) MicroRNA-135b alleviates MPP+-mediated Parkinson\u2019s disease in in vitro model through suppressing FoxO1-induced NLRP3 inflammasome and pyroptosis. J Clin Neurosci 65:125\u2013133","journal-title":"J Clin Neurosci"},{"key":"4818_CR83","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.148954","volume":"1836","author":"S Shah","year":"2024","unstructured":"Shah S et al (2024) Neuroprotective role of Carvacrol via Nrf2\/HO-1\/NLRP3 axis in Rotenone-induced PD mice model. Brain Res 1836:148954","journal-title":"Brain Res"},{"issue":"10","key":"4818_CR84","doi-asserted-by":"crossref","first-page":"9405","DOI":"10.18632\/aging.103215","volume":"12","author":"X Zhang","year":"2020","unstructured":"Zhang X et al (2020) Salidroside ameliorates Parkinson\u2019s disease by inhibiting NLRP3-dependent pyroptosis. Aging (Albany NY) 12(10):9405\u20139426","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"4818_CR85","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.kint.2024.02.023","volume":"106","author":"X Xiao","year":"2024","unstructured":"Xiao X et al (2024) Hypermethylation leads to the loss of HOXA5, resulting in JAG1 expression and NOTCH signaling contributing to kidney fibrosis. Kidney Int 106(1):98\u2013114","journal-title":"Kidney Int"},{"key":"4818_CR86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1655-5","volume":"17","author":"Z Fan","year":"2020","unstructured":"Fan Z et al (2020) Systemic activation of NLRP3 inflammasome and plasma \u03b1-synuclein levels are correlated with motor severity and progression in Parkinson\u2019s disease. J Neuroinflammation 17:1\u201310","journal-title":"J Neuroinflammation"},{"issue":"15","key":"4818_CR87","doi-asserted-by":"crossref","first-page":"2106723","DOI":"10.1002\/adma.202106723","volume":"34","author":"X Ma","year":"2022","unstructured":"Ma X et al (2022) Prussian blue nanozyme as a pyroptosis inhibitor alleviates neurodegeneration. Adv Mater 34(15):2106723","journal-title":"Adv Mater"},{"issue":"7717","key":"4818_CR88","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41586-018-0372-z","volume":"560","author":"Z Zhong","year":"2018","unstructured":"Zhong Z et al (2018) New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560(7717):198\u2013203","journal-title":"Nature"},{"issue":"34","key":"4818_CR89","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1073\/pnas.1610099113","volume":"113","author":"W Wang","year":"2016","unstructured":"Wang W et al (2016) Caspase-1 causes truncation and aggregation of the Parkinson\u2019s disease-associated protein \u03b1-synuclein. Proc Natl Acad Sci 113(34):9587\u20139592","journal-title":"Proc Natl Acad Sci"},{"key":"4818_CR90","doi-asserted-by":"crossref","first-page":"e73753","DOI":"10.7554\/eLife.73753","volume":"10","author":"YE Lin","year":"2021","unstructured":"Lin YE et al (2021) Glial Nrf2 signaling mediates the neuroprotection exerted by Gastrodia elata Blume in Lrrk2-G2019S Parkinson\u2019s disease. Elife 10:e73753","journal-title":"Elife"},{"key":"4818_CR91","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neuroscience.2020.06.001","volume":"442","author":"Y-J Ji","year":"2020","unstructured":"Ji Y-J et al (2020) Down-regulation of DJ-1 augments neuroinflammation via Nrf2\/Trx1\/NLRP3 axis in MPTP-induced Parkinson\u2019s disease mouse model. Neuroscience 442:253\u2013263","journal-title":"Neuroscience"},{"issue":"2","key":"4818_CR92","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/ijms19020562","volume":"19","author":"P Hennig","year":"2018","unstructured":"Hennig P et al (2018) The crosstalk between Nrf2 and inflammasomes. Int J Mol Sci 19(2):562","journal-title":"Int J Mol Sci"},{"issue":"43","key":"4818_CR93","doi-asserted-by":"crossref","first-page":"15514","DOI":"10.1073\/pnas.1414859111","volume":"111","author":"J Yu","year":"2014","unstructured":"Yu J et al (2014) Inflammasome activation leads to caspase-1\u2013dependent mitochondrial damage and block of mitophagy. Proc Natl Acad Sci 111(43):15514\u201315519","journal-title":"Proc Natl Acad Sci"},{"key":"4818_CR94","doi-asserted-by":"crossref","unstructured":"Panicker N et al (2022) Neuronal NLRP3 is a parkin substrate that drives neurodegeneration in Parkinson\u2019s disease. Neuron 110(15):2422\u20132437. e9","DOI":"10.1016\/j.neuron.2022.05.009"},{"key":"4818_CR95","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.neuroscience.2020.08.004","volume":"446","author":"Y-Q Yan","year":"2020","unstructured":"Yan Y-Q et al (2020) NLRP3 inflammasomes in Parkinson\u2019s disease and their regulation by Parkin. Neuroscience 446:323\u2013334","journal-title":"Neuroscience"},{"issue":"1","key":"4818_CR96","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1038\/srep05150","volume":"4","author":"Z Guo","year":"2014","unstructured":"Guo Z et al (2014) Genome-wide survey of tissue-specific microRNA and transcription factor regulatory networks in 12 tissues. Sci Rep 4(1):5150","journal-title":"Sci Rep"},{"key":"4818_CR97","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fnins.2018.00625","volume":"12","author":"AE Roser","year":"2018","unstructured":"Roser AE et al (2018) Circulating miRNAs as diagnostic biomarkers for Parkinson\u2019s disease. Front Neurosci 12:625","journal-title":"Front Neurosci"},{"key":"4818_CR98","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111800","volume":"211","author":"KP Tryphena","year":"2023","unstructured":"Tryphena KP et al (2023) Integration of miRNA\u2019s theranostic potential with nanotechnology: promises and challenges for Parkinson\u2019s disease therapeutics. Mech Ageing Dev 211:111800","journal-title":"Mech Ageing Dev"},{"issue":"5","key":"4818_CR99","first-page":"1","volume":"23","author":"X Hu","year":"2021","unstructured":"Hu X et al (2021) Potential role of microRNAs in the regulation of pyroptosis. Mol Med Rep 23(5):1\u20139","journal-title":"Mol Med Rep"},{"key":"4818_CR100","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.omtn.2021.01.022","volume":"23","author":"Q Li","year":"2021","unstructured":"Li Q et al (2021) Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson\u2019s disease. Mol Ther-Nucleic Acids 23:1334\u20131344","journal-title":"Mol Ther-Nucleic Acids"},{"issue":"6","key":"4818_CR101","volume":"11","author":"H Shen","year":"2023","unstructured":"Shen H et al (2023) NEAT1 enhances MPP+-induced pyroptosis in a cell model of Parkinson\u2019s disease via targeting miR-5047\/YAF2 signaling. Immun Inflammation Dis 11(6):e817","journal-title":"Immun Inflammation Dis"},{"key":"4818_CR102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-016-0094-3","volume":"11","author":"Y Zhou","year":"2016","unstructured":"Zhou Y et al (2016) MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson\u2019s disease. Mol Neurodegener 11:1\u201315","journal-title":"Mol Neurodegener"},{"issue":"8","key":"4818_CR103","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s10571-020-00946-8","volume":"41","author":"Q Zhang","year":"2021","unstructured":"Zhang Q et al (2021) LncRNA HOTAIR promotes neuronal damage through facilitating NLRP3 mediated-pyroptosis activation in Parkinson\u2019s disease via regulation of miR-326\/ELAVL1 axis. Cell Mol Neurobiol 41(8):1773\u20131786","journal-title":"Cell Mol Neurobiol"},{"issue":"2","key":"4818_CR104","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s13577-017-0187-5","volume":"31","author":"D Li","year":"2018","unstructured":"Li D et al (2018) MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson\u2019s disease by targeting Nlrp3. Hum Cell 31(2):106\u2013115","journal-title":"Hum Cell"},{"issue":"3","key":"4818_CR105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.17219\/acem\/154658","volume":"32","author":"Y-J Zhang","year":"2023","unstructured":"Zhang Y-J et al (2023) CircHIPK3 promotes neuroinflammation through regulation of the miR-124-3p\/STAT3\/NLRP3 signaling pathway in Parkinson\u2019s disease. Adv Clin Exp Med 32(3):315\u2013329","journal-title":"Adv Clin Exp Med"},{"issue":"6","key":"4818_CR106","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1002\/tox.22736","volume":"34","author":"MW Zhao","year":"2019","unstructured":"Zhao MW, Yang P, Zhao LL (2019) Chlorpyrifos activates cell pyroptosis and increases susceptibility on oxidative stress-induced toxicity by miR-181\/SIRT1\/PGC-1\u03b1\/Nrf2 signaling pathway in human neuroblastoma SH-SY5Y cells. Environ Toxicol 34(6):699\u2013707","journal-title":"Environ Toxicol"},{"key":"4818_CR107","first-page":"167454","volume":"8","author":"M-M Li","year":"1870","unstructured":"Li M-M et al (1870) (2024) LncRNA KCNQ1OT1 promotes NLRP3 inflammasome activation in Parkinson\u2019s disease by regulating pri-miR-186\/mature miR-186\/NLRP3 axis. Biochim Biophys Acta - Mol Basis Dis 8:167454","journal-title":"Biochim Biophys Acta - Mol Basis Dis"},{"issue":"1","key":"4818_CR108","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41392-023-01687-y","volume":"9","author":"J Yao","year":"2024","unstructured":"Yao J et al (2024) The role of inflammasomes in human diseases and their potential as therapeutic targets. Signal Transduct Target Ther 9(1):10","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"4818_CR109","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/ijms22020872","volume":"22","author":"M Sharma","year":"2021","unstructured":"Sharma M, de Alba E (2021) Structure, activation and regulation of NLRP3 and AIM2 inflammasomes. Int J Mol Sci 22(2):872","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4818_CR110","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/toxsci\/kfx117","volume":"159","author":"EM Martinez","year":"2017","unstructured":"Martinez EM et al (2017) Editor\u2019s highlight: Nlrp3 is required for inflammatory changes and nigral cell loss resulting from chronic intragastric rotenone exposure in mice. Toxicol Sci 159(1):64\u201375","journal-title":"Toxicol Sci"},{"issue":"3","key":"4818_CR111","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.3390\/ijms15033373","volume":"15","author":"D-L Fang","year":"2014","unstructured":"Fang D-L et al (2014) Development of lipid-shell and polymer core nanoparticles with water-soluble salidroside for anti-cancer therapy. Int J Mol Sci 15(3):3373\u20133388","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4818_CR112","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jss.2015.01.021","volume":"195","author":"S Liu","year":"2015","unstructured":"Liu S et al (2015) Salidroside rescued mice from experimental sepsis through anti-inflammatory and anti-apoptosis effects. J Surg Res 195(1):277\u2013283","journal-title":"J Surg Res"},{"key":"4818_CR113","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jpba.2014.11.036","volume":"105","author":"C Ma","year":"2015","unstructured":"Ma C et al (2015) An UPLC-MS-based metabolomics investigation on the anti-fatigue effect of salidroside in mice. J Pharm Biomed Anal 105:84\u201390","journal-title":"J Pharm Biomed Anal"},{"key":"4818_CR114","volume":"152","author":"M Cai","year":"2022","unstructured":"Cai M et al (2022) Kaemperfol alleviates pyroptosis and microglia-mediated neuroinflammation in Parkinson\u2019s disease via inhibiting p38MAPK\/NF-\u03baB signaling pathway. Neurochem Int 152:105221","journal-title":"Neurochem Int"},{"issue":"11","key":"4818_CR115","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1080\/15548627.2019.1596481","volume":"15","author":"X Han","year":"2019","unstructured":"Han X et al (2019) Small molecule-driven NLRP3 inflammation inhibition via interplay between ubiquitination and autophagy: implications for Parkinson disease. Autophagy 15(11):1860\u20131881","journal-title":"Autophagy"},{"issue":"1","key":"4818_CR116","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1146\/annurev-immunol-031210-101405","volume":"29","author":"BK Davis","year":"2011","unstructured":"Davis BK, Wen H, Ting JP-Y (2011) The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol 29(1):707\u2013735","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"4818_CR117","first-page":"1","volume":"7","author":"MS Dick","year":"2016","unstructured":"Dick MS et al (2016) ASC filament formation serves as a signal amplification mechanism for inflammasomes. Nat Commun 7(1):1\u201313","journal-title":"Nat Commun"},{"issue":"19","key":"4818_CR118","doi-asserted-by":"crossref","first-page":"8041","DOI":"10.1073\/pnas.0611496104","volume":"104","author":"JA Duncan","year":"2007","unstructured":"Duncan JA et al (2007) Cryopyrin\/NALP3 binds ATP\/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci 104(19):8041\u20138046","journal-title":"Proc Natl Acad Sci"},{"key":"4818_CR119","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10753-019-01098-8","volume":"43","author":"D Wu","year":"2020","unstructured":"Wu D et al (2020) Target of MCC950 in inhibition of NLRP3 inflammasome activation: a literature review. Inflammation 43:17\u201323","journal-title":"Inflammation"},{"key":"4818_CR120","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577543","volume":"354","author":"S Huang","year":"2021","unstructured":"Huang S et al (2021) A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson\u2019s disease. J Neuroimmunol 354:577543","journal-title":"J Neuroimmunol"},{"issue":"6","key":"4818_CR121","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"RC Coll","year":"2019","unstructured":"Coll RC et al (2019) MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol 15(6):556\u2013559","journal-title":"Nat Chem Biol"},{"issue":"8","key":"4818_CR122","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","volume":"17","author":"MS Mangan","year":"2018","unstructured":"Mangan MS et al (2018) Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov 17(8):588\u2013606","journal-title":"Nat Rev Drug Discov"},{"key":"4818_CR123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-019-1655-5","volume":"17","author":"R Sun","year":"2020","unstructured":"Sun R et al (2020) Low-density lipoprotein receptor (LDLR) regulates NLRP3-mediated neuronal pyroptosis following cerebral ischemia\/reperfusion injury. J Neuroinflammation 17:1\u201317","journal-title":"J Neuroinflammation"},{"issue":"11","key":"4818_CR124","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","volume":"214","author":"H Jiang","year":"2017","unstructured":"Jiang H et al (2017) Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med 214(11):3219\u20133238","journal-title":"J Exp Med"},{"issue":"1","key":"4818_CR125","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1186\/s12974-023-02830-w","volume":"20","author":"J Amo-Aparicio","year":"2023","unstructured":"Amo-Aparicio J et al (2023) Pharmacologic inhibition of NLRP3 reduces the levels of \u03b1-synuclein and protects dopaminergic neurons in a model of Parkinson\u2019s disease. J Neuroinflammation 20(1):147","journal-title":"J Neuroinflammation"},{"issue":"13","key":"4818_CR126","doi-asserted-by":"crossref","first-page":"9792","DOI":"10.1074\/jbc.M109.082305","volume":"285","author":"C Juliana","year":"2010","unstructured":"Juliana C et al (2010) Anti-inflammatory compounds parthenolide and Bay 11\u20137082 are direct inhibitors of the inflammasome. J Biol Chem 285(13):9792\u20139802","journal-title":"J Biol Chem"},{"issue":"7","key":"4818_CR127","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","volume":"115","author":"C Marchetti","year":"2018","unstructured":"Marchetti C et al (2018) OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci 115(7):E1530\u2013E1539","journal-title":"Proc Natl Acad Sci"},{"issue":"7","key":"4818_CR128","doi-asserted-by":"crossref","first-page":"E388","DOI":"10.1016\/S2665-9913(20)30166-1","volume":"2","author":"V Kluck","year":"2020","unstructured":"Kluck V, Jansen T, Janssen M (2020) Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2 alpha trial (vol 2, pg e270, 2020). Lancet Rheumatol 2(7):E388\u2013E388","journal-title":"Lancet Rheumatol"},{"issue":"3","key":"4818_CR129","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.3390\/molecules19033327","volume":"19","author":"L-M Kuo","year":"2014","unstructured":"Kuo L-M et al (2014) Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells. Molecules 19(3):3327\u20133344","journal-title":"Molecules"},{"issue":"1","key":"4818_CR130","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1038\/s41467-018-04947-6","volume":"9","author":"H He","year":"2018","unstructured":"He H et al (2018) Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun 9(1):2550","journal-title":"Nat Commun"},{"key":"4818_CR131","volume":"133","author":"K-H Lin","year":"2019","unstructured":"Lin K-H et al (2019) Oridonin, a natural diterpenoid, protected NGF-differentiated PC12 cells against MPP+- and kainic acid-induced injury. Food Chem Toxicol 133:110765","journal-title":"Food Chem Toxicol"},{"issue":"115","key":"4818_CR132","first-page":"173","volume":"21","author":"B Oronsky","year":"2016","unstructured":"Oronsky B et al (2016) Rockets, radiosensitizers, and RRx-001: an origin story part I. Discov Med 21(115):173\u2013180","journal-title":"Discov Med"},{"issue":"6","key":"4818_CR133","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41423-021-00683-y","volume":"18","author":"Y Chen","year":"2021","unstructured":"Chen Y et al (2021) RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor. Cell Mol Immunol 18(6):1425\u20131436","journal-title":"Cell Mol Immunol"},{"key":"4818_CR134","volume":"13","author":"J Fang","year":"2022","unstructured":"Fang J et al (2022) RRx-001 Exerts neuroprotection against LPS-induced microglia activation and neuroinflammation through disturbing the TLR4 pathway. Front Pharmacol 13:889383","journal-title":"Front Pharmacol"},{"key":"4818_CR135","volume":"92","author":"Y Shi","year":"2021","unstructured":"Shi Y et al (2021) NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages. Int Immunopharmacol 92:107358","journal-title":"Int Immunopharmacol"},{"issue":"9","key":"4818_CR136","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1021\/acs.jmedchem.6b01624","volume":"60","author":"M Cocco","year":"2017","unstructured":"Cocco M et al (2017) Development of an acrylate derivative targeting the NLRP3 inflammasome for the treatment of inflammatory bowel disease. J Med Chem 60(9):3656\u20133671","journal-title":"J Med Chem"},{"issue":"1","key":"4818_CR137","first-page":"326","volume":"13","author":"X Ge","year":"2021","unstructured":"Ge X et al (2021) PARK2 attenuates house dust mite-induced inflammatory reaction, pyroptosis and barrier dysfunction in BEAS-2B cells by ubiquitinating NLRP3. Am J Transl Res 13(1):326\u2013335","journal-title":"Am J Transl Res"},{"issue":"4","key":"4818_CR138","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201708689","volume":"10","author":"Y Huang","year":"2018","unstructured":"Huang Y et al (2018) Tranilast directly targets NLRP 3 to treat inflammasome-driven diseases. EMBO Mol Med 10(4):e8689","journal-title":"EMBO Mol Med"},{"issue":"3","key":"4818_CR139","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/08923973.2021.1925293","volume":"43","author":"A Saeedi-Boroujeni","year":"2021","unstructured":"Saeedi-Boroujeni A et al (2021) Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19. Immunopharmacol Immunotoxicol 43(3):247\u2013258","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"1","key":"4818_CR140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/ijc.1289","volume":"93","author":"M Platten","year":"2001","unstructured":"Platten M et al (2001) N-[3, 4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-\u03b2 release and reduces migration and invasiveness of human malignant glioma cells. Int J Cancer 93(1):53\u201361","journal-title":"Int J Cancer"},{"issue":"2","key":"4818_CR141","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s12017-021-08675-x","volume":"24","author":"P Thapak","year":"2022","unstructured":"Thapak P, Bishnoi M, Sharma SS (2022) Tranilast, a transient receptor potential vanilloid 2 channel (TRPV2) inhibitor attenuates amyloid \u03b2-induced cognitive impairment: possible mechanisms. NeuroMol Med 24(2):183\u2013194","journal-title":"NeuroMol Med"},{"issue":"2\u20133","key":"4818_CR142","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000511207","volume":"20","author":"M Zhang","year":"2020","unstructured":"Zhang M et al (2020) Suppression of NLRP3 inflammasome, pyroptosis, and cell death by NIM811 in rotenone-exposed cells as an in vitro model of Parkinson\u2019s disease. Neurodegener Dis 20(2\u20133):73\u201383","journal-title":"Neurodegener Dis"},{"issue":"1","key":"4818_CR143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"D-W Shim","year":"2017","unstructured":"Shim D-W et al (2017) BOT-4-one attenuates NLRP3 inflammasome activation: NLRP3 alkylation leading to the regulation of its ATPase activity and ubiquitination. Sci Rep 7(1):1\u201312","journal-title":"Sci Rep"},{"key":"4818_CR144","volume":"119","author":"L Liu","year":"2023","unstructured":"Liu L et al (2023) Parthenolide targets NLRP3 to treat inflammasome-related diseases. Int Immunopharmacol 119:110229","journal-title":"Int Immunopharmacol"},{"key":"4818_CR145","doi-asserted-by":"crossref","unstructured":"Liu Q et al (2020) Anti-neuroinflammatory effects of dimethylaminomylide (DMAMCL, i.e., ACT001) are associated with attenuating the NLRP3 inflammasome in MPTP-induced Parkinson disease in mice. Behav Brain Res 383:112539","DOI":"10.1016\/j.bbr.2020.112539"},{"key":"4818_CR146","volume":"379","author":"Q Liu","year":"2020","unstructured":"Liu Q et al (2020) The parthenolide derivative ACT001 synergizes with low doses of L-DOPA to improve MPTP-induced Parkinson\u2019s disease in mice. Behav Brain Res 379:112337","journal-title":"Behav Brain Res"},{"key":"4818_CR147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-020-02040-8","volume":"18","author":"Z Zhang","year":"2021","unstructured":"Zhang Z et al (2021) Blockade of the NLRP3\/caspase-1 axis attenuates ketamine-induced hippocampus pyroptosis and cognitive impairment in neonatal rats. J Neuroinflammation 18:1\u201312","journal-title":"J Neuroinflammation"},{"key":"4818_CR148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-018-0686-1","volume":"12","author":"S Xu","year":"2019","unstructured":"Xu S et al (2019) Inflammasome inhibitors: promising therapeutic approaches against cancer. J Hematol Oncol 12:1\u201313","journal-title":"J Hematol Oncol"},{"issue":"10","key":"4818_CR149","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.7150\/ijbs.24347","volume":"14","author":"F Wang","year":"2018","unstructured":"Wang F et al (2018) Alcohol accumulation promotes esophagitis via pyroptosis activation. Int J Biol Sci 14(10):1245","journal-title":"Int J Biol Sci"},{"issue":"4","key":"4818_CR150","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s11064-017-2185-0","volume":"42","author":"Z Mao","year":"2017","unstructured":"Mao Z et al (2017) The NLRP3 inflammasome is involved in the pathogenesis of Parkinson\u2019s disease in rats. Neurochem Res 42(4):1104\u20131115","journal-title":"Neurochem Res"},{"issue":"16","key":"4818_CR151","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.15252\/embj.201694696","volume":"35","author":"L Sborgi","year":"2016","unstructured":"Sborgi L et al (2016) GSDMD membrane pore formation constitutes the mechanism of pyroptotic cell death. EMBO J 35(16):1766\u20131778","journal-title":"EMBO J"},{"issue":"7575","key":"4818_CR152","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/nature15514","volume":"526","author":"J Shi","year":"2015","unstructured":"Shi J et al (2015) Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526(7575):660\u2013665","journal-title":"Nature"},{"issue":"1","key":"4818_CR153","volume":"63","author":"Z Liu","year":"2017","unstructured":"Liu Z et al (2017) Melatonin alleviates inflammasome-induced pyroptosis through inhibiting NF-\u03baB\/GSDMD signal in mice adipose tissue. J Pineal Res 63(1):e12414","journal-title":"J Pineal Res"},{"issue":"1","key":"4818_CR154","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cell.2011.11.031","volume":"148","author":"L Sun","year":"2012","unstructured":"Sun L et al (2012) Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 148(1):213\u2013227","journal-title":"Cell"},{"issue":"1","key":"4818_CR155","doi-asserted-by":"crossref","first-page":"8783","DOI":"10.1038\/s41598-023-35975-y","volume":"13","author":"YH Leem","year":"2023","unstructured":"Leem YH et al (2023) Necrosulfonamide exerts neuroprotective effect by inhibiting necroptosis, neuroinflammation, and \u03b1-synuclein oligomerization in a subacute MPTP mouse model of Parkinson\u2019s disease. Sci Rep 13(1):8783","journal-title":"Sci Rep"},{"key":"4818_CR156","doi-asserted-by":"crossref","unstructured":"Rathkey JK et al (2018) Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis. Sci Immunol 3(26):eaat2738","DOI":"10.1126\/sciimmunol.aat2738"},{"issue":"7","key":"4818_CR157","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/s41590-020-0669-6","volume":"21","author":"JJ Hu","year":"2020","unstructured":"Hu JJ et al (2020) FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation. Nat Immunol 21(7):736\u2013745","journal-title":"Nat Immunol"},{"issue":"1","key":"4818_CR158","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41565-021-00981-6","volume":"17","author":"J Kim","year":"2022","unstructured":"Kim J, Sahay G (2022) Nanomedicine hitchhikes on neutrophils to the inflamed lung. Nat Nanotechnol 17(1):1\u20132","journal-title":"Nat Nanotechnol"},{"key":"4818_CR159","volume":"38","author":"Q Liu","year":"2024","unstructured":"Liu Q et al (2024) Neutrophil hitchhiking for nanoparticle delivery to the central nervous system. Appl Mater Today 38:102259","journal-title":"Appl Mater Today"},{"key":"4818_CR160","volume":"567","author":"L Gan","year":"2019","unstructured":"Gan L et al (2019) Rabies virus glycoprotein (RVG29)-linked microRNA-124-loaded polymeric nanoparticles inhibit neuroinflammation in a Parkinson\u2019s disease model. Int J Pharm 567:118449","journal-title":"Int J Pharm"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-04818-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-04818-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-04818-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:17:55Z","timestamp":1751383075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-04818-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":160,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["4818"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-04818-4","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.\u00a0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}